Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
Su‐Kiat Chua, Wei-Ting Lai, Lung‐Ching Chen, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 13, pp. 2824-2824
Open Access | Times Cited: 22

Showing 22 citing articles:

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström, et al.
Journal of Hypertension (2023) Vol. 41, Iss. 12, pp. 1874-2071
Open Access | Times Cited: 1600
Hypertension management in patients with cardiovascular comorbidities
Lucas Lauder, Felix Mahfoud, Michel Azizi, et al.
European Heart Journal (2022) Vol. 44, Iss. 23, pp. 2066-2077
Open Access | Times Cited: 101
Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
Amr Abdin, Martin Schulz, Uwe Riemer, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 6, pp. 3737-3750
Open Access | Times Cited: 28
Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension
Utkarsh Ojha, S. Ruddaraju, N N Sabapathy, et al.
American Journal of Cardiovascular Drugs (2021) Vol. 22, Iss. 3, pp. 271-285
Open Access | Times Cited: 29
Angiotensin Receptor Blocker-Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction
Dima Nasrallah, Alaa Abdelhamid, Omar Tluli, et al.
Pharmacological Research (2024) Vol. 204, pp. 107210-107210
Open Access | Times Cited: 4
The Natriuretic Peptides for Hypertension Treatment
Speranza Rubattu, Giovanna Gallo
High Blood Pressure & Cardiovascular Prevention (2021) Vol. 29, Iss. 1, pp. 15-21
Closed Access | Times Cited: 15
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
Alberto Aimo, Michele Senni, Andrea Barison, et al.
Heart Failure Reviews (2022) Vol. 28, Iss. 1, pp. 179-191
Open Access | Times Cited: 10
Possible role of LCZ696 in atherosclerosis: new inroads and perspective
Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Engy Elekhnawy, et al.
Molecular and Cellular Biochemistry (2023) Vol. 479, Iss. 8, pp. 1895-1908
Closed Access | Times Cited: 6
European guidelines for the treatment of arterial hypertension 2023: new trends
М. В. Леонова
Meditsinskiy sovet = Medical Council (2024), Iss. 5, pp. 30-39
Open Access | Times Cited: 1
Sacubitril/Valsartan in Heart Failure with Hypertension Patients: Real-World Experiences on Different Ages, Drug Doses, and Renal Functions
Ying‐Yun Guan, Xiaoye Li, Hui Li, et al.
High Blood Pressure & Cardiovascular Prevention (2023) Vol. 30, Iss. 6, pp. 561-572
Closed Access | Times Cited: 3
Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
Xinyue Dong, Xiaoning He, Jing Wu
PharmacoEconomics (2022) Vol. 40, Iss. 12, pp. 1187-1205
Closed Access | Times Cited: 4
Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension
Yaling Zhang, Xiaoyu Zhao, Hao Huang, et al.
Clinical Research in Cardiology (2022) Vol. 112, Iss. 7, pp. 855-867
Open Access | Times Cited: 4
The Effects of Sacubitril/Valsartan Compared to Olmesartan on the Blood Pressure and Glucolipid Metabolism in DM Patients with Primary Hypertension
Shuang Zhang, Yin Zheng, Zhi-Fan Li, et al.
Cardiovascular Drugs and Therapy (2023)
Closed Access | Times Cited: 2
Review of international clinical guidelines for the management of hypertension in patients with diabetes mellitus?
Ф. О. Ушанова, T. Yu. Demidova, S. V. Panteleeva
FOCUS Endocrinology (2024) Vol. 5, Iss. 1, pp. 42-51
Open Access
Review of international clinical guidelines for the management of hypertension in patients with diabetes mellitus?
Ф. О. Ушанова, T. Yu. Demidova, S. V. Panteleeva
FOCUS Endocrinology (2024) Vol. 5, Iss. 1, pp. 42-51
Open Access
Efficacy and Safety of Sacubitril/Valsartan in Adverse Cardiovascular Event Reduction and Hypertension Control Among Asians: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Patrick Vera Cruz, Wisdom Ang, Jose Bernardo Calatrava
Philippine journal of cardiology. (2024) Vol. 52, Iss. 1, pp. 33-44
Closed Access
Recent Update on Diagnosis and Management of Hypertension: Based on the 2023 European Society of Hypertension Guidelines
Min Kyoung Kang
Journal of the Korean Neurological Association (2024) Vol. 42, Iss. 3, pp. 221-232
Open Access
The Increasing Problem of Resistant Hypertension: We’ll Manage till Help Comes!
Francesco Natale, Rosa Franzese, Ettore Luisi, et al.
Medical Sciences (2024) Vol. 12, Iss. 4, pp. 53-53
Open Access
A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
Ning Wang, Haijun Wang, Ying Chen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Convoluted molecular maze of neprilysin
Eleftherios P. Diamandis, Sok‐Ja Janket, Harry A. Conte
Diagnosis (2022) Vol. 9, Iss. 4, pp. 508-510
Closed Access | Times Cited: 1
Many drugs are available for hypertension, with more in development
Arnold Lee
Drugs & Therapy Perspectives (2022) Vol. 38, Iss. 12, pp. 520-526
Closed Access | Times Cited: 1
"Adjuvante" Hochdrucktherapie
Alexander Reshetnik
CardioVasc (2023) Vol. 23, Iss. 1, pp. 40-41
Closed Access
Page 1

Scroll to top